Why Ford Motor Company Stock Is Higher Today
Ford is on track to hit an interesting electric-vehicle milestone in 2021.
Mindfully Curated
Ford is on track to hit an interesting electric-vehicle milestone in 2021.
A public offering is weighing on the biotech’s shares today.
The Bitcoin mining specialist has expanded its capabilities and is becoming more environmentally friendly.
The FDA extended its review period for myelofibrosis candidate pacritinib.
The consumer marketplace announced its new CEO.
The Latin American fintech specialist got some love from Wall Street.
Biologists have successfully traced a naturally-produced melanoma-fighting compound called ‘palmerolide A’ to its source: a microbe that resides within Synoicum adareanum, a species of ascidian common to the waters of Antarctica’s Anvers Island archipe…
Life is water, and water is life. This truism certainly applies to the Pacific coast, where streams and rivers function as the region’s arteries. The water they carry fosters plant life and wildlife in Southern California’s Mediterranean climate. They …
DCI earnings call for the period ending October 31, 2021.
The biotech is continuing to surge after after a late-stage win in treatment for advanced ovarian cancer.
Two bits of news likely drove GAN Limited’s early day pop, but one was more important than the other.
UBS reassures that all’s well with Apple’s iPhone numbers this year.
Ambarella says it’s an AIoT company today. But what does that mean?
GIII earnings call for the period ending October 31, 2021.
Researchers have identified the first non-coding RNA that controls formation of chromosome loops, which govern gene expression. Jpx RNA was previously thought to be involved only in X chromosome inactivation, a necessary step in development of female e…
DAKT earnings call for the period ending October 30, 2021.
PDCO earnings call for the period ending October 30, 2021.
The company announced encouraging phase 2 results.
An analyst sees 164% upside in Vertex Energy.
A recent court of appeals decision is bad news for Moderna and great news for Arbutus Biopharma.